Quick Answer
Akari Therapeutics Plc reported Diluted EPS of $0.00 per share for fiscal year 2025.
Akari Therapeutics Plc Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $0.00 | — |
| 2024 | $0.00 | — |
| 2023 | $0.00 | — |
| 2022 | $0.00 | — |
| 2021 | $0.00 | +100.0% |
| 2020 | -$0.01 | +0.0% |
| 2019 | -$0.01 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.00 | — | — |
| June 30, 2025 | $0.00 | — | — |
| March 31, 2025 | $0.00 | — | — |
| September 30, 2024 | $0.00 | — | — |
| June 30, 2024 | $0.00 | — | — |
| March 31, 2024 | $0.00 | — | — |
| September 30, 2023 | $0.00 | — | — |
| June 30, 2023 | $0.00 | — | — |
- Over the 2019–2025 period, Akari Therapeutics Plc’s diluted eps has grown by 100.0% (from $0.01 per share (loss) to $0.00 per share).
- The most recent figure is from Akari Therapeutics Plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: